Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -0.10 (-0.24%)
Spread: 1.00 (2.439%)
Open: 42.50
High: 42.40
Low: 41.25
Prev. Close: 42.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
24th Apr 20202:05 pmRNSSecond Price Monitoring Extn
24th Apr 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:40 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:35 pmRNSPrice Monitoring Extension
23rd Apr 202010:18 amRNSResult of General Meeting
22nd Apr 20202:30 pmRNSHolding(s) in Company
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
22nd Apr 20207:00 amRNSAvacta/Cytiva Partnership Ahead of Schedule
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
17th Apr 20207:00 amRNSNotice of Results - Update
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20209:05 amRNSSecond Price Monitoring Extn
15th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20205:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202011:05 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 202011:05 amRNSSecond Price Monitoring Extn
8th Apr 202011:00 amRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSAvacta & Cytiva Collaborate on COVID-19 Rapid Test
6th Apr 20205:45 pmRNSHolding(s) in Company
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:01 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSProposed Placing to raise £3.75 million
2nd Apr 20207:01 amRNSAppointment of Joint Broker
2nd Apr 20207:00 amRNSSubscription to raise £2 million
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
24th Mar 20202:06 pmRNSSecond Price Monitoring Extn
24th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSShareholder/Investor Meeting and Presentation
13th Feb 20207:00 amRNSNotice of Results
11th Feb 20207:00 amRNSShare Incentive Plan/Issue of Equity
3rd Feb 20207:00 amRNSAvacta and Daewoong Agreement
29th Jan 20202:45 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSSuccessful initial proof-of-concept

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.